1Higuera-Ciapara I, Félix-Valenzuela L & Goyocoolea FM (2006) Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr 46, 186–196.
2Miki W (1991) Biological functions and activities of animal carotenoids. Pure Appl Chem 63, 141–146.
3Pashkow FJ, Watumull DG & Campbell CL (2008) Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 101, 58D–68D.
4Comhaire FH, El Garem Y, Mahmoud A, et al. (2008) Combined conventional/antioxidant ‘astaxanthin’ treatment for male infertility: a double blind, randomized trial. Asian J Androl 7, 257–262.
5Kupcinskas L, Lafolie P, Lignell A, et al. (2008) Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: a prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 15, 391–399.
6Parisi V, Tedeschi M, Gallinaro G, et al. (2008) Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology 115, 324–344.
7Nagao A (2009) Absorption and function of dietary carotenoids. Forum Nutr 61, 55–63.
8Odeberg JM, Lignell A, Pettersson A, et al. (2003) Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 19, 299–304.
9Okada Y, Ishikura M & Maoka T (2009) Bioavailability of astaxanthin in Haematococcus algal extract: the effects of timing of diet and smoking habits. Biosci Biotechnol Biochem 73, 1928–1932.
10Showalter LA, Weinman SA, Østerlie M, et al. (2004) Plasma appearance and tissue accumulation of non-esterified, free astaxanthin in C57BL/6 mice after oral dosing of a disodium disuccinate diester of astaxanthin (Heptax). Comp Biochem Physiol C Toxicol Pharmacol 137, 227–236.
11Petri D & Lundebye AK (2007) Tissue distribution of astaxanthin in rats following exposure to graded levels in the feed. Comp Biochem Physiol C Toxicol Pharmacol 145, 202–209.
12Kistler A, Liechti H, Pichard L, et al. (2002) Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch Toxicol 75, 665–675.
13Erich W, Hans L, Brightte N, et al. (1999) Characterization of metabolites of astaxanthin in primary cultures of rat hepatocytes. Drug Metab Dispos 27, 456–462.
14Correia MA (1995) Appendices B. Rat and human liver cytochromes 450: substrate and inhibitor specificities and functional markers. In Cytochrome 450. Structure, Mechanism, and Biochemistry, 2nd ed., pp. 607–630. New York: Plenum Press.
15Kim SH, Choi YM & Lee MG (1993) Pharmacokinetics and pharmacodynamics of furosemide in protein–calorie malnutrition. J Pharmacokinet Biopharm 21, 1–7.
16Murakami T, Nakanishi M, Yoshimori T, et al. (2003) Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18, 242–260.
17Choi YH, Kim SG & Lee MG (2006) Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95, 2543–2552.
18Williams JF, Lowitt S & Szentivanyi A (1979) Effect of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in rats. Biochem Pharmacol 28, 2935–2940.
19Choi YM, Kim SH & Lee MG (1991) Effect of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J Pharm Sci 80, 638–642.
20Lee DY, Kim JY, Kim YC, et al. (2005) Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. Biopharm Drug Dispos 26, 173–182.
21Yu SY, Bae SK & Kim EJ (2003) Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J Pharm Sci 92, 1592–1603.
22Gibaldi M & Perrier D (1980) Pharmacokinetics, 2nd ed.New York: Marcel Dekker.
23Chiou WL (1978) Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6, 539–546.
24Boxenbaum H (1998) Pharmacokinetics tricks and traps: flip-flop models. J Pharm Pharm Sci 1, 90–91.
25Goto S, Kogure K, Abe K, et al. (2001) Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta 1512, 251–258.
26Zhi J, Melia AT, Koss-Twardy SG, et al. (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 36, 152–159.
27Xu MJ, Plezia PM, Alberts DS, et al. (1992) Reduction in plasma or skin alpha-tocopherol concentration with long-term oral administration of beta-carotene in humans and mice. J Natl Cancer Inst 84, 1559–1565.
28White WS, Stacewicz-Sapuntzakis M, Erdman JW Jr, et al. (1994) Pharmacokinetics of beta-carotene and canthaxanthin after ingestion of individual and combined doses by human subjects. J Am Coll Nutr 13, 665–671.